November 1, 2020 | Volume 80 | Number 21

CANCER RESEARCH

TABLE OF CONTENTS

BREAKING INSIGHTS

REVIEWS

CANCER RESEARCH HIGHLIGHTS

PRIORITY REPORT

GENOME AND EPIGENOME

TABLE OF CONTENTS

MOLECULAR CELL BIOLOGY

TUMOR BIOLOGY AND IMMUNOLOGY

See related commentary, p. 4610

TABLE OF CONTENTS

TRANSLATIONAL SCIENCE

CONVERGENCE AND TECHNOLOGIES

AC AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

TABLE OF CONTENTS

ABOUT THE COVER

Acquired resistance to EGFR tyrosine kinase inhibitors such as osimertinib involves both EGFR resistance mutations and EGFR-independent mechanisms (e.g., activation of alternate receptor tyrosine kinases). Sun and colleagues reported the discovery of IACS-13909, an allosteric inhibitor of SHP2 that is able to overcome both types of resistance mechanisms in preclinical models. Targeting SHP2 may present a promising strategy to tackle the plasticity and heterogeneity of tyrosine kinase inhibitor resistance. For details, see article by Sun and colleagues on page 4840.



Cancer Research
The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

AACR American Association for Cancer Research

80 (21)

Cancer Res 2020;80:4591-4867.